Skip to main content
MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED logo

MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED — Investor Relations & Filings

Ticker · MVP ISIN · AU000000MVP2 LEI · 9845007EAECAOD1U4493 ASX Manufacturing
Open in API
Filings indexed 908 across all filing types
Latest filing 2018-07-17 Remuneration Information
Country AU Australia
Listing ASX MVP

About MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED

https://medicaldev.com

Medical Developments International Limited specializes in the development and distribution of emergency pain relief and respiratory products. The company's flagship product is Penthrox, a handheld, self-administered inhaler providing rapid-onset, non-opioid analgesia using methoxyflurane. Penthrox is utilized globally by emergency medical services, hospitals, and for procedural pain in various clinical settings. Additionally, the company manufactures a range of respiratory medical devices, including anti-static spacers and asthma management tools designed to optimize medication delivery. The organization focuses on providing portable, effective solutions for acute pain management and respiratory care, catering to healthcare professionals and patients in emergency, surgical, and primary care environments.

Recent filings

Filing Released Lang Actions
CEO Long Term Incentive Plan 2 pages 117.4KB
Remuneration Information Classification · 95% confidence The document is an ASX announcement dated 18 July 2018 regarding a Long Term Incentive Plan (LTIP) granted to the CEO of Medical Developments International Limited. It details the grant of options to the CEO and the terms of the plan. The document is short (2407 characters) and explicitly states that detailed information will be included in the FY18 Annual Report, indicating this is a summary announcement rather than the full report. The content focuses on management compensation arrangements rather than financial results or governance structure. Therefore, the document fits best under Remuneration Information (DEF 14A) as it details compensation-related information for a top executive.
2018-07-17 English
Penthrox approved in Spain 2 pages 204.9KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 16 July 2018, stating that the product Penthrox has been approved for sale in Spain. It includes quotes from the CEO and general company information. The document is short (2641 characters) and does not contain any financial data, regulatory filings, or detailed reports. It is a straightforward announcement about product approval, which fits best under a general regulatory announcement category rather than a financial or management report. Therefore, the most appropriate classification is Regulatory Filings (RNS), which is the fallback for miscellaneous announcements that do not fit other categories.
2018-07-15 English
Penthrox approved in Italy and the Czech Republic 2 pages 207.4KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 10 July 2018 about the approval of the product Penthrox in Italy and the Czech Republic. It contains no financial data, no detailed report, no regulatory certification, or voting results. The document is short (2517 characters) and primarily serves as a news announcement about product approval and market expansion. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or any detailed financial or governance report. It is a general regulatory announcement about product approval and market entry, which fits best under Regulatory Filings (RNS) as a miscellaneous announcement that does not fit other categories.
2018-07-09 English
Appendix 3B 12 pages 390.4KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of new securities, including the class, number, terms, issue price, purpose, and compliance with ASX listing rules. It includes sections on placement capacity calculations under ASX rules 7.1 and 7.1A, quotation agreements, and other regulatory compliance details related to new share issues. The content is focused on announcing and detailing a new share issue and application for quotation of additional securities. This matches the definition of a 'Share Issue/Capital Change' filing, which covers announcements regarding new share issues or capital changes. The document is lengthy (15,000 characters) and contains substantive details about the share issuance, not merely an announcement of a report or a certification. Therefore, the appropriate classification is 'SHA' for Share Issue/Capital Change.
2018-07-01 English
Penthrox approved in Portugal and Switzerland 2 pages 200.3KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 25 June 2018, announcing the approval of the product Penthrox in Portugal and Switzerland. It contains no financial statements, no detailed financial data, no management discussion, or regulatory certifications. The document is a brief update on product approval and market expansion, typical of a capital/financing or business update. It is not an earnings release, annual report, or any detailed financial report. Given the nature of the announcement about product approval and market rollout, it fits best under Capital/Financing Update (CAP) as it relates to business expansion and potential sales growth. The document length is short (2782 characters), and it is not a report publication announcement or regulatory filing. Therefore, the classification is CAP with high confidence.
2018-06-24 English
Iran Distribution Deal and additional European Approvals 2 pages 407.5KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 29 May 2018, detailing a new exclusive distribution deal for Iran and approvals of the product Penthrox in several European countries. It discusses regulatory approval progress and orders for delivery in FY19. The content focuses on business development, product approvals, and distribution agreements rather than financial results, management changes, or regulatory filings. The document length is 4289 characters, which is relatively short and typical for a market announcement. There is no indication that this is a full financial report, earnings release, or management discussion. It is clearly an announcement about a commercial agreement and regulatory approvals, which fits best under Capital/Financing Update (CAP) as it relates to business expansion and distribution deals impacting the company's capital and market presence.
2018-05-28 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.